Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:ENTL
- CUSIP: N/A
- Web: www.entellusmedical.com
Capitalization:- Market Cap: $342.77 million
- Outstanding Shares: 21,916,000
Average Prices:- 50 Day Moving Avg: $13.50
- 200 Day Moving Avg: $15.48
- 52 Week Range: $11.47 - $22.63
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.77
- P/E Growth: -0.56
Sales & Book Value:- Annual Revenue: $77.39 million
- Price / Sales: 4.43
- Book Value: $3.42 per share
- Price / Book: 4.57
Profitability:- EBIDTA: ($25,430,000.00)
- Net Margins: -39.02%
- Return on Equity: -60.56%
- Return on Assets: -35.90%
Debt:- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 4.57%
- Quick Ratio: 4.21%
Misc:- Average Volume: 169,988 shs.
- Beta: 0.04
- Short Ratio: 6.61
Frequently Asked Questions for Entellus Medical (NASDAQ:ENTL)
What is Entellus Medical's stock symbol?
Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."
How were Entellus Medical's earnings last quarter?
Entellus Medical, Inc. (NASDAQ:ENTL) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. The firm had revenue of $19.11 million for the quarter, compared to the consensus estimate of $19.61 million. Entellus Medical had a negative net margin of 39.02% and a negative return on equity of 60.56%. The business's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.37) EPS. View Entellus Medical's Earnings History.
When will Entellus Medical make its next earnings announcement?
Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?
7 brokerages have issued 1 year price targets for Entellus Medical's shares. Their forecasts range from $16.00 to $26.00. On average, they expect Entellus Medical's share price to reach $22.00 in the next year. View Analyst Ratings for Entellus Medical.
What are analysts saying about Entellus Medical stock?
Here are some recent quotes from research analysts about Entellus Medical stock:
- 1. According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (5/9/2017)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)
Who are some of Entellus Medical's key competitors?
Some companies that are related to Entellus Medical include Novadaq Technologies (NVDQ), REGENXBIO (RGNX), La Jolla Pharmaceutical Company (LJPC), Civitas Solutions (CIVI), Sangamo BioSciences (SGMO), CryoLife (CRY), CRISPR THERAPTC (CRSP), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Meridian Bioscience (VIVO), Cytokinetics, Incorporated (CYTK), Reata Pharmaceuticals (RETA), MacroGenics (MGNX), AMAG Pharmaceuticals (AMAG), Versartis (VSAR), Akebia Therapeutics (AKBA), PTC Therapeutics (PTCT) and Ignyta (RXDX).
Who are Entellus Medical's key executives?
Entellus Medical's management team includes the folowing people:
- Robert S. White, President, Chief Executive Officer, Director
- Brent A. Moen, Chief Financial Officer, Corporate Secretary
- Jonelle R. Burnham, Chief Compliance Officer, Vice President, General Counsel
- Stephen R. Paidosh, Vice President, Operations
- Thomas D. Williamson, Vice President - Sales
- Kevin L. Mensink, Vice President of Marketing
- Martha J. Christian, Vice President, Reimbursement
- Timothy B. Petrick, Vice President, Research and Development
- Brian E. Farley, Non-Executive Chairman of the Board
- John K. Bakewell, Independent Director
When did Entellus Medical IPO?
(ENTL) raised $70 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Who owns Entellus Medical stock?
Entellus Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SV Health Investors LLC (13.51%),
DISCOVERY GROUP I, LLC
(9.60%), FMR LLC (2.73%), Frontier Capital Management Co. LLC (2.24%), Kingdon Capital Management L.L.C. (2.05%) and Vanguard Group Inc. (2.04%). Company insiders that own Entellus Medical stock include Brent Moen, Brian E Farley, James D Surek, Joshua J Baltzell, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano, Robert S White and Timothy B Petrick. View Institutional Ownership Trends for Entellus Medical.
Who sold Entellus Medical stock? Who is selling Entellus Medical stock?
Entellus Medical's stock was sold by a variety of institutional investors in the last quarter, including SV Health Investors LLC, FMR LLC, Renaissance Technologies LLC, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have sold Entellus Medical stock in the last year include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano and Timothy B Petrick. View Insider Buying and Selling for Entellus Medical.
Who bought Entellus Medical stock? Who is buying Entellus Medical stock?
Entellus Medical's stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, William Blair Investment Management LLC, Kingdon Capital Management L.L.C., Grandeur Peak Global Advisors LLC, Vanguard Group Inc., Laurion Capital Management LP, Royce & Associates LP and Blair William & Co. IL. Company insiders that have bought Entellus Medical stock in the last two years include Brent Moen, Joshua J Baltzell and Robert S White. View Insider Buying and Selling for Entellus Medical.
How do I buy Entellus Medical stock?
Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Entellus Medical's stock price today?
One share of Entellus Medical stock can currently be purchased for approximately $15.64.
MarketBeat Community Rating for Entellus Medical (NASDAQ ENTL)MarketBeat's community ratings are surveys of what our community members think about Entellus Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Entellus Medical (NASDAQ:ENTL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.43) |
| Consensus Price Target: | $22.00 (40.66% upside) |
Analysts' Ratings History for Entellus Medical (NASDAQ:ENTL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/22/2017 | Canaccord Genuity | Set Price Target | Hold | $18.00 | Low |  |
| 5/10/2017 | William Blair | Reiterated Rating | Outperform | | Low | |
| 2/22/2017 | Bank of America Corporation | Downgrade | Buy -> Underperform | $16.00 | N/A | |
| 2/22/2017 | BTIG Research | Downgrade | Buy -> Neutral | | N/A | |
| 12/14/2016 | Piper Jaffray Companies | Reiterated Rating | Positive | | N/A | |
| 12/6/2016 | Guggenheim | Initiated Coverage | Buy | $25.00 | N/A | |
| 11/4/2016 | Deutsche Bank AG | Reiterated Rating | Buy | $25.00 -> $26.00 | N/A | |
(Data available from 6/26/2015 forward)
Earnings History for Entellus Medical (NASDAQ:ENTL)Earnings History by Quarter for Entellus Medical (NASDAQ ENTL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | | | | | | | |
| 5/3/2017 | Q1 2017 | ($0.44) | ($0.40) | $19.61 million | $19.11 million | View | Listen | |
| 2/21/2017 | Q4 2016 | ($0.33) | ($0.39) | $21.58 million | $21.70 million | View | Listen | |
| 11/3/2016 | Q3 | ($0.37) | ($0.50) | $17.93 million | $17.90 million | View | Listen | |
| 8/3/2016 | Q2 | ($0.35) | ($0.27) | $18.48 million | $18.73 million | View | Listen | |
| 5/4/2016 | Q1 | ($0.47) | ($0.37) | $16.34 million | $16.90 million | View | Listen | |
| 2/24/2016 | Q4 | ($0.26) | ($0.27) | $17.52 million | $18.07 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.25) | ($0.32) | $14.19 million | $14.80 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.20) | ($0.15) | $15.00 million | $15.20 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Entellus Medical (NASDAQ:ENTL)2017 EPS Consensus Estimate: ($1.35)
2018 EPS Consensus Estimate: ($0.94)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.38) | ($0.38) | ($0.38) |
| Q2 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q3 2017 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q4 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q1 2018 | 1 | ($0.32) | ($0.32) | ($0.32) |
| Q2 2018 | 1 | ($0.22) | ($0.22) | ($0.22) |
| Q3 2018 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q4 2018 | 1 | ($0.13) | ($0.13) | ($0.13) |
(Data provided by Zacks Investment Research)
Dividend History for Entellus Medical (NASDAQ:ENTL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Entellus Medical (NASDAQ:ENTL)Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 75.79%
Insider Trades by Quarter for Entellus Medical (NASDAQ:ENTL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/8/2017 | Brent Moen | CFO | Buy | 6,100 | $12.21 | $74,481.00 | |
| 5/8/2017 | Joshua J Baltzell | Director | Buy | 1,600 | $12.34 | $19,744.00 | |
| 5/8/2017 | Robert S. White | Insider | Buy | 10,000 | $12.24 | $122,400.00 | |
| 1/31/2017 | Life Sciences Fu International | Major Shareholder | Sell | 533,077 | $17.00 | $9,062,309.00 | |
| 1/13/2017 | Brian E Farley | Director | Sell | 14,019 | $20.14 | $282,342.66 | |
| 1/13/2017 | Karen E. Peterson | VP | Sell | 10,000 | $20.13 | $201,300.00 | |
| 1/10/2017 | Brian E Farley | Director | Sell | 9,842 | $19.11 | $188,080.62 | |
| 1/10/2017 | Karen E. Peterson | VP | Sell | 9,840 | $19.11 | $188,042.40 | |
| 1/4/2017 | Brian E Farley | Director | Sell | 20,158 | $18.74 | $377,760.92 | |
| 1/4/2017 | Karen E Peterson | VP | Sell | 10,160 | $18.74 | $190,398.40 | |
| 12/6/2016 | Brian E Farley | Director | Sell | 15,000 | $18.57 | $278,550.00 | |
| 11/23/2016 | Brian E Farley | Director | Sell | 5,000 | $19.00 | $95,000.00 | |
| 11/18/2016 | Brian E Farley | Director | Sell | 10,000 | $18.30 | $183,000.00 | |
| 10/13/2016 | Margaret A. Boiano | VP | Sell | 11,103 | $20.01 | $222,171.03 | |
| 10/5/2016 | Brian E Farley | Director | Sell | 30,000 | $22.26 | $667,800.00 | |
| 9/8/2016 | James D Surek | VP | Sell | 10,000 | $18.71 | $187,100.00 | |
| 9/2/2016 | Brian E Farley | Director | Sell | 11,078 | $18.62 | $206,272.36 | |
| 9/1/2016 | Brian E Farley | Director | Sell | 17,006 | $19.33 | $328,725.98 | |
| 9/1/2016 | Kevin L. Mensink | VP | Sell | 8,000 | $18.39 | $147,120.00 | |
| 8/1/2016 | Kevin L Mensink | VP | Sell | 8,100 | $17.63 | $142,803.00 | |
| 7/18/2016 | Timothy B. Petrick | VP | Sell | 3,000 | $18.15 | $54,450.00 | |
| 2/11/2016 | Karen E Peterson | Insider | Sell | 5,000 | $16.00 | $80,000.00 | |
| 2/4/2016 | Karen E Peterson | Insider | Sell | 10,000 | $17.00 | $170,000.00 | |
| 9/17/2015 | Brian E. Farley | Chairman | Sell | 5,484 | $22.00 | $120,648.00 | |
| 9/15/2015 | Brian E. Farley | Chairman | Sell | 27,619 | $22.18 | $612,589.42 | |
| 9/14/2015 | Brian E. Farley | Chairman | Sell | 21,187 | $22.15 | $469,292.05 | |
| 9/2/2015 | James D Surek | VP | Sell | 15,000 | $21.27 | $319,050.00 | |
| 8/31/2015 | James D. Surek | VP | Sell | 5,000 | $22.29 | $111,450.00 | |
| 2/3/2015 | Robert S White | COO | Buy | 5,882 | $17.00 | $99,994.00 | |
| 2/3/2015 | Shawn Mccormick | Director | Buy | 2,941 | $17.00 | $49,997.00 | |
| 2/3/2015 | Woodlands Health Venture Essex | Major Shareholder | Buy | 352,941 | $17.00 | $5,999,997.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Entellus Medical (NASDAQ:ENTL)
Latest Headlines for Entellus Medical (NASDAQ:ENTL)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Expect Entellus Medical, Inc. (ENTL) Will Post Quarterly Sales of $21.17 Million
www.americanbankingnews.com - June 23 at 4:00 PM |
| Zacks: Analysts Anticipate Entellus Medical, Inc. (ENTL) to Announce -$0.34 EPS
www.americanbankingnews.com - June 21 at 12:08 PM |
 | ETFs with exposure to Entellus Medical, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:37 PM |
| ETFs with exposure to Entellus Medical, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 5:59 PM |
| Entellus Medical, Inc. :ENTL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 5:24 PM |
| Entellus Medical Inc (ENTL) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 6:46 PM |
| Entellus Medical to Present at the William Blair Growth Stock Conference
finance.yahoo.com - June 1 at 5:45 PM |
| Entellus Medical Inc (ENTL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 30 at 8:00 AM |
| $21.17 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 28 at 9:54 AM |
| -$0.34 Earnings Per Share Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - May 26 at 8:54 AM |
| Canaccord Genuity Analysts Give Entellus Medical Inc (ENTL) a $18.00 Price Target
www.americanbankingnews.com - May 23 at 9:20 PM |
| Entellus Medical Inc (ENTL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 23 at 5:04 PM |
| The Centers for Medicare & Medicaid Services (CMS) Establishes Coding and Payment for Eustachian Tube Balloon Dilation
finance.yahoo.com - May 22 at 4:43 PM |
| Q2 2017 Earnings Estimate for Entellus Medical Inc Issued By William Blair (ENTL)
www.americanbankingnews.com - May 12 at 10:20 AM |
| Q2 2018 Earnings Forecast for Entellus Medical Inc Issued By William Blair (ENTL)
www.americanbankingnews.com - May 11 at 2:14 PM |
| Entellus Medical Inc (ENTL) Earns "Outperform" Rating from William Blair
www.americanbankingnews.com - May 10 at 3:26 PM |
| Entellus Medical Inc (ENTL) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:38 PM |
| Entellus Medical Inc (ENTL) Director Buys $19,744.00 in Stock
www.americanbankingnews.com - May 8 at 10:08 PM |
| Entellus Medical Inc (ENTL) Insider Acquires $122,400.00 in Stock
www.americanbankingnews.com - May 8 at 8:23 PM |
| Brent Moen Acquires 6,100 Shares of Entellus Medical Inc (ENTL) Stock
www.americanbankingnews.com - May 8 at 8:22 PM |
| Entellus Medical Inc (ENTL) Rating Lowered to Hold at Canaccord Genuity
www.americanbankingnews.com - May 7 at 12:26 PM |
| Investor Network: Entellus Medical, Inc. to Host Earnings Call
finance.yahoo.com - May 5 at 3:11 AM |
 | Mid-Day Market Update: Crude Oil Down 4%; Insight Enterprises Shares Surge After Strong Q1 Results
www.nasdaq.com - May 4 at 5:08 PM |
| Here's Why Entellus Medical Inc. Stock Is Under the Weather Today
finance.yahoo.com - May 4 at 5:08 PM |
 | Here's Why Entellus Medical Inc. Stock Is Under the Weather Today
www.fool.com - May 4 at 2:41 PM |
| Entellus Medical Inc (ENTL) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 3 at 7:40 PM |
 | Entellus reports 1Q loss
marketbeat.com - May 3 at 6:05 PM |
| Entellus Medical Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 4:51 PM |
| Entellus Medical Inc (ENTL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 3 at 8:42 AM |
| Entellus Medical (ENTL) Given News Impact Score of 0.31
www.americanbankingnews.com - May 2 at 6:38 PM |
| Entellus Medical (ENTL) Getting Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 28 at 2:00 PM |
| Entellus Medical Inc (ENTL) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 25 at 7:53 PM |
| Entellus Medical Inc (ENTL) Short Interest Update
www.americanbankingnews.com - April 24 at 5:54 PM |
| Entellus Medical, Inc. – Value Analysis (NASDAQ:ENTL) : April 24, 2017
finance.yahoo.com - April 24 at 4:49 PM |
| Entellus Medical (ENTL) Earns Daily Coverage Optimism Rating of 0.12
www.americanbankingnews.com - April 24 at 10:44 AM |
| Entellus Medical (ENTL) Earning Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 2:40 PM |
| Entellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : April 21, 2017
finance.yahoo.com - April 21 at 11:59 AM |
| Entellus Medical to Present at the Deutsche Bank Annual Health Care Conference
finance.yahoo.com - April 20 at 5:06 PM |
 | Entellus Medical to Report First Quarter 2017...
www.benzinga.com - April 19 at 9:57 PM |
| Entellus Medical to Report First Quarter 2017 Financial Results on May 3, 2017
finance.yahoo.com - April 19 at 9:57 PM |
| Entellus Medical (ENTL) Getting Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 18 at 4:06 PM |
| Entellus Medical (ENTL) Given Daily News Impact Score of 0.28
www.americanbankingnews.com - April 15 at 9:45 AM |
| $19.47 Million in Sales Expected for Entellus Medical Inc (ENTL) This Quarter
www.americanbankingnews.com - April 13 at 11:31 AM |
| Canaccord Genuity Reiterates Buy Rating for Entellus Medical Inc (ENTL)
www.americanbankingnews.com - April 12 at 9:32 PM |
| Entellus Medical Receives FDA 510(k) Clearance for Eustachian Tube Indication
finance.yahoo.com - April 12 at 5:01 PM |
| Entellus Medical Inc (ENTL) Expected to Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - April 11 at 6:07 PM |
| Entellus Medical Inc (ENTL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 7 at 9:05 PM |
| ETFs with exposure to Entellus Medical, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 9:38 AM |
| Entellus Medical, Inc. (ENTL)
finance.yahoo.com - March 29 at 11:34 AM |
| Entellus Medical Inc (ENTL) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 28 at 8:08 AM |
Entellus Medical (ENTL) Chart for Monday, June, 26, 2017
